Hauser R A, Olanow C W
Department of Neurology, University of South Florida, Tampa.
Mov Disord. 1993 Oct;8(4):512-4. doi: 10.1002/mds.870080417.
Dyskinesia is a common adverse effect complicating chronic dopaminergic therapy for Parkinson's disease. Movements are frequently choreic in nature and have been ascribed to overstimulation of "supersensitive" striatal postsynaptic dopamine receptors. Anticholinergic medications, despite some clinical efficacy in Parkinson's disease, have rarely been reported to cause dyskinesia. We report a patient with Parkinson's disease who developed orobuccal dyskinesia while being treated with trihexyphenidyl (Artane). Dyskinesia was observed following the introduction of trihexyphenidyl, resolved with its discontinuation, and reappeared with its reinstitution. Carbidopa-levodopa (Sinemet) alone did not cause dyskinesia but augmented dyskinesia associated with trihexyphenidyl.
运动障碍是帕金森病慢性多巴胺能治疗中常见的一种不良副作用。其动作通常具有舞蹈病的性质,被认为是“超敏”纹状体突触后多巴胺受体过度刺激所致。抗胆碱能药物尽管在帕金森病中有一定临床疗效,但很少有报道称其会引起运动障碍。我们报告一名帕金森病患者,在接受苯海索(安坦)治疗时出现口颊部运动障碍。在引入苯海索后观察到运动障碍,停药后缓解,再次用药时又出现。单独使用卡比多巴 - 左旋多巴(息宁)不会引起运动障碍,但会加重与苯海索相关的运动障碍。